Spectrum Pharmaceuticals, Inc.
157 Technology Drive
559 articles with Spectrum Pharmaceuticals, Inc.
Spectrum Pharmaceuticals, Inc. announced that due to the U.S. Food and Drug Administration’s request for additional manufacturing-related information for ROLONTIS, the company has voluntarily withdrawn its Biologics License Application.
Spectrum Pharmaceuticals to Present Corporate Update at the Oppenheimer 29th Annual Healthcare Conference on March 20
Spectrum Pharmaceuticals announced that an overview of the company's business strategy and development-stage programs will be given at the Oppenheimer 29th Annual Healthcare Conference being held in New York.
Spectrum Pharmaceuticals, Inc. completed the sale of its portfolio of seven FDA-approved hematology/oncology products to Acrotech Biopharma L.L.C., a step-down subsidiary of Aurobindo Pharma Limited, India.
Spectrum Pharmaceuticals Reports Fourth Quarter 2018 and Full Year 2018 Financial Results and Pipeline Update
Spectrum Pharmaceuticals, Inc. (NASDAQ-GS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today financial results for the three-month period and year ended December 31, 2018.
Spectrum Pharmaceuticals Announces Fourth Quarter and Full Year 2018 Financial Results Conference Call
Spectrum Pharmaceuticals, announced it will host a conference call with management to discuss the fourth quarter and full year 2018 financial results, provide an update on the company's business, and discuss expectations for the future on Thursday, February 28, 2019 at 4:30 p.m. Eastern/1:30 p.m. Pacific.
Spectrum Pharmaceuticals to Present Corporate Update at the Guggenheim Healthcare Talks Idea Forum on February 14
Spectrum Pharmaceuticals announced that an overview of the company's business strategy and development-stage programs will be given at the Guggenheim Healthcare Talks Idea Forum | Oncology Day being held in New York.
Spectrum Pharmaceuticals Sells Marketed Portfolio to Acrotech Biopharma L.L.C. to Focus on New and Innovative Therapies for Cancer Patients
Spectrum will receive $160 million in an upfront cash payment and up to $140 million in regulatory and sales-based milestones
Acrotech Biopharma, a New Jersey-based subsidiary of Aurobindo Pharma USA, is buying Henderson, Nevada-based Spectrum Pharmaceuticals’ seven FDA-approved hematology/oncology products.
Spectrum Pharmaceuticals Announces Full Enrollment of the Poziotinib EGFR Cohort for Previously Treated Non-Small Cell Lung Cancer Patients with Exon 20 Insertion Mutations
Results are expected in the second half of 2019
Spectrum Pharmaceuticals Announces Submission of Biologics License Application to the FDA for ROLONTIS® (eflapegrastim) as a Treatment for Chemotherapy-Induced Neutropenia
Submission based on results from two large, positive pivotal trials
Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), today announced that based on a subset of data from MD Anderson’s ongoing Phase 2 study, the U.S. Food and Drug Administration (FDA) did not grant Breakthrough Therapy Designation (BTD) to poziotinib for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have EGFR exon 20 mutations.
Spectrum Pharmaceuticals Announces Results from the RECOVER Phase 3 Study of ROLONTIS® (eflapegrastim) at the 2018 SABCS Annual Meeting
Primary endpoint of non-inferiority in the Duration of Severe Neutropenia (DSN) between ROLONTIS and pegfilgrastim was met
Spectrum Pharmaceuticals Announces Positive Results from Phase 2 Trial Evaluating Use of Oral Leucovorin to Potentially Mitigate Mucositis in Patients Treated with FOLOTYN® (pralatrexate)
In practice, FOLOTYN use has caused Grade 2 or higher oral mucositis in more than half of patients, potentially impacting treatment of relapsed or refractory Peripheral T-cell Lymphoma (PTCL)
Spectrum Pharmaceuticals Highlights Three Posters at the 60th Annual Meeting of the American Society of Hematology
Spectrum Pharmaceuticals today announced presentations of clinical and scientific data related to Peripheral T-cell Lymphoma (PTCL) and EVOMELA® (melphalan) at the 60th Annual Meeting of the American Society of Hematology (ASH) being held in San Diego, California, from December 1-4, 2018.
The American Society of Hematology is holding its 60th Annual Meeting & Exposition starting December 1 and running through December 4 in San Diego. Most of the players, big and small, in cancer drug therapies will be there, presenting updates and breaking stories about their hematology pipelines.
Spectrum Pharmaceuticals Inc. today announced the appointment of Jeffrey Vacirca, MD, FACP to its Board of Directors.
Poziotinib interim data from the MD Anderson Phase 2 study presented in Q3 demonstrated strong efficacy in metastatic, heavily pretreated EGFR and HER2 exon 20 mutations in NSCLC patients
Spectrum Pharmaceuticals to Present Corporate Update at the Jefferies 2018 London Healthcare Conference on November 14
Spectrum Pharmaceuticals today announced that an overview of the company's business strategy and commercial and development-stage programs will be given at the Jefferies 2018 London Healthcare Conference being held in London.
Spectrum Pharmaceuticals today announced it will host a teleconference and webcast with management to discuss the third quarter 2018 financial results.
KHAPZORY is not indicated for the treatment of pernicious anemia and megaloblastic anemia secondary to lack of vitamin B12 because of the risk of progression of neurologic manifestations despite hematologic remission.